Abstract
BackgroundPaediatric patients with rheumatic diseases have a higher risk of infections. The treatment with anti-IL 1 drugs (anakinra/canakinumab) can increase the occurrence of infectious diseasesObjectivesThe aim of this study is...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
